期刊文献+

抗体类生物治疗药物活性测定方法 被引量:10

Progress in Research and Development of Bioactivity Determination of Antibody-based Therapeutics
原文传递
导出
摘要 抗体类生物治疗药物的活性测定在质量控制中至关重要。目前抗体药物的活性分析方法主要是体外(in vitro)检测,其中基于细胞的分析方法由于其具有操作简便,周期短,特异性好,变异度小等优点得到广泛应用。为了获得反应性理想的细胞和简便易行的检测方法,构建转基因细胞成为目前常用的策略之一。此外,一些新型技术也快速应用于抗体类药物的活性评价中。结合抗体类生物治疗药物活性测定方法的现状以及发展趋势,主要从基于细胞、转基因细胞以及新技术应用三方面对抗体药物活性测定方法进行简要综述,为抗体药物的研发和质量控制提供新思路。 Bioactivity determination of antibody-based therapeutics is essential in quality control. Presently,the main method to determine bioactivity is in vitro assay. Cell-based determination is widely used because of its advantages,such as simple operation,short period,good specificity and small variation,etc. In order to obtain the cell lines with ideal reactivity and simple detection method,construction of transgenic cell lines become one of the common strategies. In addition,some new technologies have rapidly been applied to evaluate the bioactivity of antibody drugs. Combined with the current research status and trend in development of bioactivity determination method,three aspects of antibody bioassay methods,which are based on cells,genetically modified cells and new technologies were described,thus providing new ideas for drug development and quality control.
出处 《中国生物工程杂志》 CAS CSCD 北大核心 2015年第6期101-108,共8页 China Biotechnology
基金 国家"重大新药创制"科技重大专项(2012ZX09304010 2014ZX09304311-001)资助项目
关键词 抗体类生物治疗药物 活性测定 转基因细胞 表面等离子共振 均相时间分辨荧光 Alpha技术 Antibody-based therapeutics Bioactivity determination Transgenic cell Surface plasmon resonance Homogeneous time-resolved fluore
  • 相关文献

参考文献23

二级参考文献76

  • 1饶春明,赵阳,李永红,王军志.应用荧光法测定重组细胞因子中残余DNA含量[J].药物分析杂志,2005,25(12):1417-1419. 被引量:22
  • 2张岩锐,段丽娟,苟凝虹,徐枫.重组CHO-C_(28)细胞染色体鉴定方法的研究[J].微生物学免疫学进展,2006,34(4):40-43. 被引量:1
  • 3Lau SC, Rosa DI), Jayson G. Technology evaluation: VEGF Trap (cancer), regeneron/sanofi-aventis. Curr Opin Mol Ther, 2005, 7 (5): 493-501.
  • 4Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA, 2002, 99 (17): 11393-11398.
  • 5Riely GJ, Miller VA. Vascular endothelial growth factor trap in non small cell lung cancer. Clin Cancer Res, 2007, 13 (15pt2): s4623-s4627.
  • 6Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic maeular oedema. Br J Ophthalmol, 2009, 93 (2): 144-149.
  • 7Kaiser PK. Vascular endothelial growth factor Trap-Eye for diabetic macular oedema. Br J Ophthalmol, 2009, 93 (2): 135-136.
  • 8Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap-Regeneron, VEGF Trap (RIR2), VEGF Trap-Eye. Drugs RD, 2008, 9 (4): 261-269.
  • 9Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs, 2009, 18 (5): 637-646.
  • 10Gomez-Manzano C, Holash J, Fueyo J, et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol, 2008, 10 (6): 940-945,.

共引文献66

同被引文献41

引证文献10

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部